NLRP3 inflammasome inhibitors have been disclosed in a Kodiak Sciences Inc. patent and described as useful for the treatment of atherosclerosis, gout, rheumatoid arthritis, inflammatory bowel, Alzheimer’s, Parkinson diseases, multiple sclerosis and glaucoma.